3006 POSTER DISCUSSION Time to Deterioration (TTD) in Patient-reported Outcomes in Phase 3 AXis Trial of Axitinib Vs Sorafenib as Second-line Therapy for Metastatic Renal Cell Carcinoma (mRCC)

✍ Scribed by D. Cella; B. Escudier; B. Rini; C. Chen; H. Bhattacharyya; J. Tarazi; B. Rosbrook; S. Kim; R. Motzer

• Book ID: 117661571
• Publisher: Elsevier Science
• Year: 2011
• Tongue: English
• Weight: 44 KB
• Volume: 47
• Category: Article
• ISSN: 0959-8049
• DOI: 10.1016/s0959-8049(11)71079-6